iRadimed (NASDAQ:IRMD – Get Free Report) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share guidance of 2.090-2.240 for the period, compared to the consensus EPS estimate of 1.960. The company issued revenue guidance of $91.0 million-$96.0 million, compared to the consensus revenue estimate of $91.2 million. iRadimed also updated its Q3 2026 guidance to 0.540-0.590 EPS.
iRadimed Stock Performance
Shares of NASDAQ:IRMD opened at $90.86 on Friday. The business has a fifty day moving average of $94.54 and a 200-day moving average of $95.70. iRadimed has a twelve month low of $57.83 and a twelve month high of $107.90. The firm has a market cap of $1.16 billion, a PE ratio of 50.76 and a beta of 0.90.
iRadimed (NASDAQ:IRMD – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.02. The business had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, analysts anticipate that iRadimed will post 1.52 EPS for the current fiscal year.
iRadimed Dividend Announcement
Analyst Ratings Changes
Separately, Weiss Ratings downgraded iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, iRadimed has a consensus rating of “Buy” and a consensus target price of $120.00.
Get Our Latest Stock Analysis on IRMD
Insider Activity at iRadimed
In related news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the transaction, the chief executive officer directly owned 2,162,500 shares in the company, valued at $195,922,500. This represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 21,250 shares of company stock worth $1,836,403. 34.60% of the stock is owned by insiders.
Key iRadimed News
Here are the key news stories impacting iRadimed this week:
- Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
- Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
- Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
- Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
- Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Boothbay Fund Management LLC acquired a new position in shares of iRadimed during the 3rd quarter worth approximately $279,000. Cerity Partners LLC acquired a new stake in iRadimed in the fourth quarter valued at $261,000. Brevan Howard Capital Management LP acquired a new position in shares of iRadimed during the 2nd quarter worth about $260,000. PharVision Advisers LLC bought a new stake in shares of iRadimed in the 3rd quarter valued at about $257,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after purchasing an additional 234 shares during the period. Institutional investors own 92.34% of the company’s stock.
About iRadimed
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Read More
- Five stocks we like better than iRadimed
- Netflix’s Big Sell-Off May Be Sending the Wrong Signal
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
